Evidence map›Paper›PMID 40694184›Full record

ArticleMedical oncology (Northwood, London, England)2025

Combination of PSMA targeting alpha-emitting radioligand [

Rugile Liukaityte, Vilde Yuli Stenberg, Andrius Kleinauskas, Petras Juzenas, Alfonso Urbanucci, Asta Juzeniene

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rugile LiukaityteDepartment of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0009-0009-7547-3287
Vilde Yuli StenbergARTBIO AS, Oslo, Norway.ORCID http://orcid.org/0000-0003-4329-5411
Andrius KleinauskasDepartment of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-6679-6705
Petras JuzenasDepartment of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-0114-903X
Alfonso UrbanucciDepartment of Tumour Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0003-2931-3652
Asta JuzenieneDepartment of Radiation Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. astaj@ous-hf.no.ORCID http://orcid.org/0000-0001-9426-0062

Funding

Kreftforeningen 273672 & 198016Radforsk, Oslo, Norway TARACANResearch Council of Finland 349314The European Union's Horizon 2020 research and innovation programme No 101008571 (PRISMAP)
6 · The paper itself

Abstract

The alpha-emitting radioligand [

Indexed as

Antigens, SurfaceGlutamate Carboxypeptidase IIProstatic NeoplasmsApoptosisAzepinesBromodomain Containing ProteinsCell Line, TumorCell ProliferationCell SurvivalHumansMaleProteinsTriazolesAntigens, SurfaceAzepinesbromodomain and extra-terminal domain protein, humanBromodomain Containing ProteinsFOLH1 protein, humanGlutamate Carboxypeptidase II(+)-JQ1 compoundProteinsTriazolesBromodomain and extra-terminal proteinsCell cycleCombination treatmentTargeted alpha therapyTargeted radionuclide therapy

Identifiers

PMID40694184
PMCPMC12283873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.